Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fiona Brown

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Bioorganic & Medicinal Chemistry Letters|November 6, 2010
The identification of novel orally active mGluR5 antagonist GSK2210875Maria Pilla, Michela Andreoli, Michela Tessari, et al.
Nephrology (Carlton, Vic.)|May 8, 2020
Baseline characteristics of patients with atypical haemolytic uraemic syndrome (aHUS): The Australian cohort in a global aHUS registryJacqueline Soraru, Nicole Isbel, Germaine Wong, et al.
Bioorganic & Medicinal Chemistry Letters|August 17, 2010
The discovery of a series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles as highly brain penetrant, selective muscarinic M1 agonistsDale J Johnson, Ian T Forbes, Steve P Watson, et al.
Plos One|May 14, 2021
Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphomaShelby L Sloan, Kyle A Renaldo, Mackenzie Long, et al.
Blood Advances|December 15, 2022
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cellsCharis E Teh, Hongke Peng, Meng-Xiao Luo, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2019
BCL-2 family protein BOK is a positive regulator of uridine metabolism in mammalsRahul Srivastava, Zhipeng Cao, Christina Nedeva, et al.
Blood Advances|October 2, 2023
Resistance to PRMT5-targeted therapy in mantle cell lymphomaMackenzie Elizabeth Long, Shirsha Koirala, Shelby Sloan, et al.
Journal of Biomolecular Screening|January 7, 2012
Configuration of a high-content imaging platform for hit identification and pharmacological assessment of JMJD3 demethylase enzyme inhibitorsAlpa Mulji, Carl Haslam, Fiona Brown, et al.
Blood Advances|June 16, 2023
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphomaFiona Brown-Burke, Inah Hwang, Shelby Sloan, et al.
Kidney International Reports|August 15, 2022
Establishing a Core Outcome Measure for Peritoneal Dialysis-related Peritonitis: A Standardized Outcomes in Nephrology-Peritoneal Dialysis Consensus Workshop ReportJenny I Shen, Yeoungjee Cho, Karine E Manera, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Bioorganic & Medicinal Chemistry Letters|November 6, 2010
The identification of novel orally active mGluR5 antagonist GSK2210875Maria Pilla, Michela Andreoli, Michela Tessari, et al.
Nephrology (Carlton, Vic.)|May 8, 2020
Baseline characteristics of patients with atypical haemolytic uraemic syndrome (aHUS): The Australian cohort in a global aHUS registryJacqueline Soraru, Nicole Isbel, Germaine Wong, et al.
Bioorganic & Medicinal Chemistry Letters|August 17, 2010
The discovery of a series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles as highly brain penetrant, selective muscarinic M1 agonistsDale J Johnson, Ian T Forbes, Steve P Watson, et al.
Plos One|May 14, 2021
Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphomaShelby L Sloan, Kyle A Renaldo, Mackenzie Long, et al.
Blood Advances|December 15, 2022
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cellsCharis E Teh, Hongke Peng, Meng-Xiao Luo, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2019
BCL-2 family protein BOK is a positive regulator of uridine metabolism in mammalsRahul Srivastava, Zhipeng Cao, Christina Nedeva, et al.
Blood Advances|October 2, 2023
Resistance to PRMT5-targeted therapy in mantle cell lymphomaMackenzie Elizabeth Long, Shirsha Koirala, Shelby Sloan, et al.
Journal of Biomolecular Screening|January 7, 2012
Configuration of a high-content imaging platform for hit identification and pharmacological assessment of JMJD3 demethylase enzyme inhibitorsAlpa Mulji, Carl Haslam, Fiona Brown, et al.
Blood Advances|June 16, 2023
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphomaFiona Brown-Burke, Inah Hwang, Shelby Sloan, et al.
Kidney International Reports|August 15, 2022
Establishing a Core Outcome Measure for Peritoneal Dialysis-related Peritonitis: A Standardized Outcomes in Nephrology-Peritoneal Dialysis Consensus Workshop ReportJenny I Shen, Yeoungjee Cho, Karine E Manera, et al.
Pageof 5